Free Trial
NASDAQ:CTMX

CytomX Therapeutics (CTMX) Stock Price, News & Analysis

CytomX Therapeutics logo
$2.49 +0.01 (+0.36%)
As of 03:14 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About CytomX Therapeutics Stock (NASDAQ:CTMX)

Key Stats

Today's Range
$2.44
$2.52
50-Day Range
$0.65
$2.99
52-Week Range
$0.40
$3.10
Volume
755,737 shs
Average Volume
3.44 million shs
Market Capitalization
$200.66 million
P/E Ratio
5.19
Dividend Yield
N/A
Price Target
$5.33
Consensus Rating
Buy

Company Overview

CytomX Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
85th Percentile Overall Score

CTMX MarketRank™: 

CytomX Therapeutics scored higher than 85% of companies evaluated by MarketBeat, and ranked 128th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    CytomX Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    CytomX Therapeutics has only been the subject of 3 research reports in the past 90 days.

  • Read more about CytomX Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for CytomX Therapeutics are expected to decrease in the coming year, from ($0.05) to ($0.33) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of CytomX Therapeutics is 5.19, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 25.55.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of CytomX Therapeutics is 5.19, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 27.43.

  • Read more about CytomX Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    27.61% of the float of CytomX Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    CytomX Therapeutics has a short interest ratio ("days to cover") of 4.3.
  • Change versus previous month

    Short interest in CytomX Therapeutics has recently increased by 9.65%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    CytomX Therapeutics does not currently pay a dividend.

  • Dividend Growth

    CytomX Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    27.61% of the float of CytomX Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    CytomX Therapeutics has a short interest ratio ("days to cover") of 4.3.
  • Change versus previous month

    Short interest in CytomX Therapeutics has recently increased by 9.65%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    CytomX Therapeutics has a news sentiment score of 0.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for CytomX Therapeutics this week, compared to 2 articles on an average week.
  • Search Interest

    15 people have searched for CTMX on MarketBeat in the last 30 days. This is an increase of 15% compared to the previous 30 days.
  • MarketBeat Follows

    Only 2 people have added CytomX Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, CytomX Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 6.60% of the stock of CytomX Therapeutics is held by insiders.

  • Percentage Held by Institutions

    67.77% of the stock of CytomX Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about CytomX Therapeutics' insider trading history.
Receive CTMX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CytomX Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CTMX Stock News Headlines

CytomX Therapeutics, Inc. (CTMX) - Yahoo Finance
I was wrong about Trump
I made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his advisors, I believed him. I believed the promise that he would finally confront the single most dangerous threat to American life. That he would fix the ticking time bomb I’ve been warning about for 15 years. But I was wrong.
See More Headlines

CTMX Stock Analysis - Frequently Asked Questions

CytomX Therapeutics' stock was trading at $1.03 on January 1st, 2025. Since then, CTMX shares have increased by 141.7% and is now trading at $2.4890.

CytomX Therapeutics, Inc. (NASDAQ:CTMX) announced its quarterly earnings data on Monday, May, 12th. The biotechnology company reported $0.27 earnings per share for the quarter, beating the consensus estimate of $0.18 by $0.09. The biotechnology company earned $50.92 million during the quarter, compared to analysts' expectations of $35.42 million. CytomX Therapeutics had a negative trailing twelve-month return on equity of 553.71% and a net margin of 28.22%.
Read the conference call transcript
.

Shares of CTMX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that CytomX Therapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), Arista Networks (ANET), Meta Platforms (META), CymaBay Therapeutics (CBAY), Adobe (ADBE) and CrowdStrike (CRWD).

Company Calendar

Last Earnings
5/12/2025
Today
7/03/2025
Next Earnings (Estimated)
8/14/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:CTMX
Employees
170
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$5.33
High Stock Price Target
$6.00
Low Stock Price Target
$5.00
Potential Upside/Downside
+114.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Trailing P/E Ratio
5.19
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$31.87 million
Pretax Margin
28.35%

Debt

Sales & Book Value

Annual Sales
$138.10 million
Cash Flow
$0.38 per share
Price / Cash Flow
6.52
Book Value
($0.01) per share
Price / Book
-248.90

Miscellaneous

Free Float
75,300,000
Market Cap
$200.66 million
Optionable
Optionable
Beta
2.05

Social Links

Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

This page (NASDAQ:CTMX) was last updated on 7/3/2025 by MarketBeat.com Staff
From Our Partners